Type 2 diabetes mellitus (T2D), a formidable and growing challenge to the VA healthcare system, represents a heterogenous set of hyperglycemic disorders involving impaired insulin secretion, insulin resistance, and increased hepatic glucose production. Both insufficient insulin secretion from ? cells and dysregulated, typically increased, glucagon secretion from ? cells, contribute to the hyperglycemia in T2D. While many hypotheses and models exist, the molecular mechanisms responsible for human islet dysfunction in T2D are incompletely defined and largely unknown or unproven. Most models and hypotheses about the T2D ? cell arise from studies of rodent models and have not been confirmed or tested in human samples. Because of the many differences in human and rodent islets, it is critical to study potential regulators in a human islet context and that will be a focus of this proposal. This proposed studies are based on evidence that islets from donors with short-duration T2D have impaired insulin secretion, enhanced glucagon secretion, and reduced expression of PAX6, an islet-enriched transcription factor recently shown in rodent systems critical to islet ? cell identify and functional maintenance. Very little is known about the role of PAX6 is human islet cells. The proposed studies will test the hypothesis that PAX6 is required for normal human ? and ? cell function and that reduced PAX6 expression contributes to T2D islet ? and ? cell dysfunction in these aims: (1) Determine the functional and transcriptional consequences of PAX6 transcriptional control normal human islets in vitro; (2) Determine the functional consequences of PAX6 loss from normal human ? or ? cells in vivo; (3) Assess whether PAX6 loss in short-duration T2D islets is reversed by treatment with a Glucagon-like Peptide-1 (GLP-1) agonist. By employing innovative experimental approaches such as creation of human pseudoislets in which gene expression can be modified and transplantation of genetically modified human pseudoislets into immunodeficient, glucagon-less mouse model (NSG-GKO) to allow for the assessment of ? and ? cell function in vitro and in vivo, these studies will expand our understanding of the molecular processes regulating human ? and ? cell function and islet dysfunction, leading to new clinically actionable information for T2D treatment.

Public Health Relevance

We do not understand what causes type 2 diabetes, but defects in the pancreatic islet and insulin secretion play a major role. Much of our knowledge has come from studies of rodent cells or rodents with diabetes, but this is problematic because human islets have critical differences from rodent islets. In this grant, we will use new technologies and experimental approaches to genetically manipulate non-diabetic, human islets to understand factors that effect their normal function. We will also study islets from individuals with type 2 diabetes to understand how common treatment improves the function of these diseased islets.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
2I01BX000666-09
Application #
10012458
Study Section
Special Emphasis Panel (ZRD1)
Project Start
2010-07-01
Project End
2024-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
9
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Veterans Health Administration
Department
Type
DUNS #
156385783
City
Nashville
State
TN
Country
United States
Zip Code
37212
Brissova, Marcela; Haliyur, Rachana; Saunders, Diane et al. (2018) ? Cell Function and Gene Expression Are Compromised in Type 1 Diabetes. Cell Rep 22:2667-2676
Marre, Meghan L; McGinty, John W; Chow, I-Ting et al. (2018) Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes. Diabetes 67:1356-1368
Dean, E Danielle; Li, Mingyu; Prasad, Nripesh et al. (2017) Interrupted Glucagon Signaling Reveals Hepatic ? Cell Axis and Role for L-Glutamine in ? Cell Proliferation. Cell Metab 25:1362-1373.e5
Bozadjieva, Nadejda; Blandino-Rosano, Manuel; Chase, Jennifer et al. (2017) Loss of mTORC1 signaling alters pancreatic ? cell mass and impairs glucagon secretion. J Clin Invest 127:4379-4393
Aamodt, Kristie I; Powers, Alvin C (2017) Signals in the pancreatic islet microenvironment influence ?-cell proliferation. Diabetes Obes Metab 19 Suppl 1:124-136
Arda, H Efsun; Li, Lingyu; Tsai, Jennifer et al. (2016) Age-Dependent Pancreatic Gene Regulation Reveals Mechanisms Governing Human ? Cell Function. Cell Metab 23:909-20
Delong, Thomas; Wiles, Timothy A; Baker, Rocky L et al. (2016) Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351:711-4
Ceddia, Ryan P; Lee, DaeKee; Maulis, Matthew F et al. (2016) The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice. Endocrinology 157:220-32
Boortz, Kayla A; Syring, Kristen E; Dai, Chunhua et al. (2016) G6PC2 Modulates Fasting Blood Glucose In Male Mice in Response to Stress. Endocrinology 157:3002-8
Dai, Chunhua; Kayton, Nora S; Shostak, Alena et al. (2016) Stress-impaired transcription factor expression and insulin secretion in transplanted human islets. J Clin Invest 126:1857-70

Showing the most recent 10 out of 36 publications